Global Phase 3 Randomized Study Comparing Intravenous Telisotuzumab Adizutecan plus Bevacizumab Versus Oral TrifluridineTipiracil plus Bevacizumab in Adults with Refractory Metastatic Colorectal Cancer
Led by AbbVie · Updated on 2026-10-19
990
Participants Needed
88
Research Sites
43 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and disease activity changes of telisotuzumab adizutecan combined with bevacizumab compared to the standard treatment of trifluridine and tipiracil LONSURF plus bevacizumab in adults with refractory metastatic colorectal cancer. This Phase 3 study aims to enroll about 990 participants worldwide to better understand these treatments in this patient group.
Participants will be randomly assigned to one of two groups one group will receive intravenous telisotuzumab adizutecan with bevacizumab, while the other group will receive the standard of care, which includes oral trifluridine and tipiracil plus intravenous bevacizumab. Treatment will continue for approximately 36 months.
During the study, participants will attend regular visits at approved hospitals or clinics where medical assessments, blood tests, questionnaires, and side effect monitoring will take place. The main outcomes measured include objective response up to 15 months and overall survival up to 36 months, with additional measures such as progression-free survival and duration of response tracked up to 24 months. This ongoing monitoring aims to understand the impact and safety of the treatments over time.
CONDITIONS
Brief Title
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
Research Team
A
ABBVIE CALL CENTER
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Must voluntarily sign and date an informed consent approved by an Ethics Committee or Institutional Review Board before any study procedures
Have a life expectancy of at least 12 weeks as assessed by the investigator
You will not qualify if you...
Prior treatment with c-Met targeting agents or any Top-1 inhibitor antibody drug conjugates
History of intolerance or allergic reactions to bevacizumab, trifluridine, tipiracil, or similar compounds including rare hereditary problems like galactose intolerance
History of hypersensitivity to Chinese Hamster Ovary cell products or other recombinant human or humanized antibodies
History of significant drug or alcohol abuse within the last 6 months
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Approximately 36 months
Participants receive either intravenous telisotuzumab adizutecan plus bevacizumab or the standard oral trifluridine and tipiracil plus intravenous bevacizumab. Treatment and monitoring continue for approximately 36 months.
Regular visits at approved hospitals or clinics
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Study of 177LuBetaBart Monoclonal Antibody for Safety and Early Effects in Adults With Advanced Solid Tumors
Evaluating 18F-T2 PETCT Imaging for Detecting Tumors with High CAIX Levels in Adults
Phase 12a Study of 64Cu-LNTH-1363S PETCT Imaging in Patients with Sarcoma or Gastrointestinal Tract Cancer
Evaluating Safety, Dosage, and Imaging Correlation with FAP Expression
Study of 18FFPyQCP PET Imaging for Fibroblast Activation Protein in Selected Cancers
Phase 2 Study of 68GaBED003 PET Imaging for Detecting Fibroblast Activation Protein in Colorectal, Gastric, Pancreatic, Breast, and Ovarian Cancers
Study Evaluating Sacituzumab Tirumotecan Alone or With Other Cancer Treatments for Advanced Gastrointestinal Cancers
Evaluating TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Adults With HER2-Abnormal Locally Advanced or Metastatic Colorectal Cancer
Phase I Study of Intravenous CEA-Targeted CAR-T Therapy for Advanced CEA Positive Solid Tumors
Community Screening Study Using Polygene Methylation Testing for Colorectal Cancer in Yangzhou Residents Aged 40 to 74
Study Comparing Early and Late Onset Colorectal Cancer
Investigating Clinical, Socioeconomic, Genetic, and Molecular Factors
Assessing Cancer Recurrence and Survival Outcomes
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
A randomized Phase 1 study of telisotuzumab adizutecan (ABBV-400, Temab-A) in combination with bevacizumab versus trifluridine-tipiracil with bevacizumab in patients with metastatic colorectal cancer.